Citation Impact
Citing Papers
A Fluoroquinolone Resistance Protein from Mycobacterium tuberculosis That Mimics DNA
2005 Science
Fitness Costs of Fluoroquinolone Resistance in Streptococcus pneumoniae
2006
In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and Skin Structure Infections
2019
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis
2009
Construction of Robust Bio‐nanotubes using the Controlled Self‐Assembly of Component Proteins of Bacteriophage T4
2010 StandoutNobel
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
2007 Standout
Molecular mechanisms of antibiotic resistance
2014 Standout
Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults
2000 Standout
Emerging Mechanisms of Fluoroquinolone Resistance
2001
Biology‐Oriented Synthesis
2011
A global perspective on the use, sales, exposure pathways, occurrence, fate and effects of veterinary antibiotics (VAs) in the environment
2006 Standout
DNA topoisomerases: harnessing and constraining energy to govern chromosome topology
2008
Antimicrobial Resistance with Streptococcus pneumoniae in the United States, 1997–98
1999
Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine
2003 Standout
Fluoroquinolone resistance among Gram-positive cocci
2002
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
2011 Standout
Decreased Susceptibility ofStreptococcus pneumoniaeto Fluoroquinolones in Canada
1999
DNA gyrase as a drug target
1997
Optical control of antibacterial activity
2013 StandoutNobel
A Mutation in Yeast Topoisomerase II That Confers Hypersensitivity to Multiple Classes of Topoisomerase II Poisons
2000
Mechanisms of antibiotic resistance and tolerance in
2000 StandoutNobel
Antituberculosis drugs: Ten years of research
2007
Visible-light photoredox catalyzed synthesis of pyrroloisoquinolines via organocatalytic oxidation/[3 + 2] cycloaddition/oxidative aromatization reaction cascade with Rose Bengal
2014
Antibacterial resistance worldwide: causes, challenges and responses
2004 Standout
The Science of Antibiotic Discovery
2020 Standout
Antibiotic resistance and its cost: is it possible to reverse resistance?
2010 Standout
The Regulation of Sulfur Metabolism in Mycobacterium tuberculosis
2011 StandoutNobel
Clinical Features and Prognostic Factors in Adults with Bacterial Meningitis
2004 Standout
Mechanisms of Fluoroquinolone Resistance: An Update 1994-1998
1999
Outpatient antibiotic use in Europe and association with resistance: a cross-national database study
2005 Standout
Understanding the mechanisms and drivers of antimicrobial resistance
2015 Standout
Structure of QnrB1, a Plasmid-mediated Fluoroquinolone Resistance Factor
2011
Visible‐Light‐Induced Oxidation/[3+2] Cycloaddition/Oxidative Aromatization Sequence: A Photocatalytic Strategy To Construct Pyrrolo[2,1‐a]isoquinolines
2011
Increasing Prevalence of Multidrug-ResistantStreptococcus pneumoniaein the United States
2000
Sequential assembly of the septal cell envelope prior to V snapping in Corynebacterium glutamicum
2019 StandoutNobel
Visible‐Light Photoredox Catalysis
2012 Standout
Multi-targeting by monotherapeutic antibacterials
2006
Fluoroquinolones: Action and Resistance
2003
Urban wastewater treatment plants as hotspots for antibiotic resistant bacteria and genes spread into the environment: A review
2013 Standout
Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success
2014
Call of the wild: antibiotic resistance genes in natural environments
2010 Standout
Implant infections: adhesion, biofilm formation and immune evasion
2018 Standout
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
A Dominant Complement Fixation Pathway for Pneumococcal Polysaccharides Initiated by SIGN-R1 Interacting with C1q
2006 StandoutNobel
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
2010 Standout
Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance
2010
ATP binding controls distinct structural transitions of Escherichia coli DNA gyrase in complex with DNA
2012
A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics
2007 Standout
Mechanism of Quinolone Action and Resistance
2014 Standout
Antibacterial drug discovery in the resistance era
2016 StandoutNature
Invasive Methicillin-Resistant <EMPH TYPE="ITAL">Staphylococcus aureus</EMPH> Infections in the United States
2007 Standout
Photolytic and photocatalytic decomposition of aqueous ciprofloxacin: Transformation products and residual antibacterial activity
2010
targetTB: A target identification pipeline for Mycobacterium tuberculosis through an interactome, reactome and genome-scale structural analysis
2008
Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America
2019 Standout
Guidelines for the Management of Adults with Community-acquired Pneumonia
2001 Standout
Treatment of drug-resistant pneumococcal pneumonia
2002
Synthesis of H-Pyrazolo[5,1-a]isoquinolines via Copper(II)-Catalyzed Oxidation of an Aliphatic C−H Bond of Tertiary Amine in Air
2011
Visible‐Light‐Induced Oxidation/[3+2] Cycloaddition/Oxidative Aromatization Sequence: A Photocatalytic Strategy To Construct Pyrrolo[2,1‐a]isoquinolines
2011
Biologically active quinoline and quinazoline alkaloids part I
2017
Chan–Lam coupling reactions: synthesis of heterocycles
2012
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Biological Cost of Single and Multiple Norfloxacin Resistance Mutations in Escherichia coli Implicated in Urinary Tract Infections
2005
New Mechanistic and Functional Insights into DNA Topoisomerases
2013
Antibiotic tolerance and the alternative lifestyles of Staphylococcus aureus
2017
Organic Photoredox Catalysis
2016 Standout
Synthesis of phenoxyquinolin-4(1H)-one through copper(II)-mediated cross-coupling of phenylboronic acid and hydroxyquinolin-4(1H)-one
2005
Biologically active quinoline and quinazoline alkaloids part II
2018
TROSY in triple-resonance experiments: New perspectives for sequential NMR assignment of large proteins
1998 StandoutNobel
Mutation Rate and Evolution of Fluoroquinolone Resistance in Escherichia coli Isolates from Patients with Urinary Tract Infections
2003
Homologation of the Fischer Indolization: A Quinoline Synthesis via Homo‐Diaza‐Cope Rearrangement
2020 StandoutNobel
Bacterial Resistance to β-Lactam Antibiotics: Compelling Opportunism, Compelling Opportunity
2005 Standout
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Besifloxacin, a Novel Fluoroquinolone, Has Broad-Spectrum In Vitro Activity against Aerobic and Anaerobic Bacteria
2009
Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
2010
Sampling the Antibiotic Resistome
2006 StandoutScience
Fluorine in Pharmaceuticals: Looking Beyond Intuition
2007 StandoutScience
Effects of pharmaceutical mixtures in aquatic microcosms
2004
Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance
2001 Standout
Aerobic Copper-Catalyzed Organic Reactions
2013 Standout
Artificial Molecular Machines
2015 Standout
Drugging Topoisomerases: Lessons and Challenges
2012
Cas9 interrogates DNA in discrete steps modulated by mismatches and supercoiling
2020 StandoutNobel
Bacterial Topoisomerase Inhibitors: Quinolone and Pyridone Antibacterial Agents
2005
Viridans Group Streptococci Are Donors in Horizontal Transfer of Topoisomerase IV Genes to Streptococcus pneumoniae
2003
Amino acid variation in the GyrA subunit of bacteria potentially associated with natural resistance to fluoroquinolone antibiotics
1997
Emerging Targets in Photopharmacology
2016 StandoutNobel
DNA gyrase, topoisomerase IV, and the 4-quinolones
1997
Visible Light Photoredox Catalysis with Transition Metal Complexes: Applications in Organic Synthesis
2013 Standout
Efficacy and Safety of Nemonoxacin versus Levofloxacin for Community-Acquired Pneumonia
2010
Visible‐Light Photocatalysis: Does It Make a Difference in Organic Synthesis?
2018 Standout
Solar Synthesis: Prospects in Visible Light Photocatalysis
2014 StandoutScience
Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide
2011 StandoutScience
Challenges of Antibacterial Discovery
2011
Antimicrobial Resistance in ESKAPE Pathogens
2020 Standout
DNA Topoisomerases: Structure, Function, and Mechanism
2001 Standout
Works of Xiao-Su Pan being referenced
Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli
2009
Breakage-Reunion Domain of Streptococcus pneumoniae Topoisomerase IV: Crystal Structure of a Gram-Positive Quinolone Target
2007
Structural Basis of Gate-DNA Breakage and Resealing by Type II Topoisomerases
2010
Structural insight into the quinolone–DNA cleavage complex of type IIA topoisomerases
2009
Structure of an ‘open’ clamp type II topoisomerase-DNA complex provides a mechanism for DNA capture and transport
2013
Streptococcus pneumoniae DNA Gyrase and Topoisomerase IV: Overexpression, Purification, and Differential Inhibition by Fluoroquinolones
1999
Ciprofloxacin Dimers Target Gyrase in Streptococcus pneumoniae
2004
Functional determinants of gate-DNA selection and cleavage by bacterial type II topoisomerases
2013
Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
1996
Correction: Structural Basis of Gate-DNA Breakage and Resealing by Type II Topoisomerases
2010
Probing the Differential Interactions of Quinazolinedione PD 0305970 and Quinolones with Gyrase and Topoisomerase IV
2009
Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance
1996
DNA Gyrase and Topoisomerase IV Are Dual Targets of Clinafloxacin Action in Streptococcus pneumoniae
1998
Cleavable-Complex Formation by Wild-Type and Quinolone-Resistant Streptococcus pneumoniae Type II Topoisomerases Mediated by Gemifloxacin and Other Fluoroquinolones
2002
Grepafloxacin, a Dimethyl Derivative of Ciprofloxacin, Acts Preferentially through Gyrase in Streptococcus pneumoniae : Role of the C-5 Group in Target Specificity
2002
Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones
1997
Quinolone Resistance Mutations in Streptococcus pneumoniae GyrA and ParC Proteins: Mechanistic Insights into Quinolone Action from Enzymatic Analysis, Intracellular Levels, and Phenotypes of Wild-Type and Mutant Proteins
2001
Engineering the Specificity of Antibacterial Fluoroquinolones: Benzenesulfonamide Modifications at C-7 of Ciprofloxacin Change Its Primary Target in Streptococcus pneumoniae from Topoisomerase IV to Gyrase
2000
Small-Colony Mutants of Staphylococcus aureus Allow Selection of Gyrase-Mediated Resistance to Dual-Target Fluoroquinolones
2002
Mycobacterium tuberculosis DNA Gyrase: Interaction with Quinolones and Correlation with Antimycobacterial Drug Activity
2004